Xeris Biopharma Holdings, Inc. Stock price
Equities
XERS
US98422E1038
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.185 USD | +7.11% | +2.58% | -7.02% |
Financials (USD)
Sales 2024 * | 184M | Sales 2025 * | 219M | Capitalization | 287M |
---|---|---|---|---|---|
Net income 2024 * | -55M | Net income 2025 * | -27M | EV / Sales 2024 * | 1.55 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
-5.3
x | P/E ratio 2025 * |
-11.1
x | Employees | 377 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.13% |
Latest transcript on Xeris Biopharma Holdings, Inc.
1 day | +7.11% | ||
1 week | +2.58% | ||
Current month | -28.94% | ||
1 month | -27.65% | ||
3 months | -7.42% | ||
6 months | +16.22% | ||
Current year | -7.02% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 04-12-31 | |
Paul Edick
CEO | Chief Executive Officer | 67 | 21-10-04 |
Steven Pieper
DFI | Director of Finance/CFO | 47 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Johnson
BRD | Director/Board Member | 66 | 21-10-04 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 21-10-04 |
Marla Persky
BRD | Director/Board Member | 68 | 21-10-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 8 M€ | +9.29% | - | |
0.00% | 142 M€ | +6.18% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.2 | +7.84% | 2 277 648 |
24-03-27 | 2.04 | -0.49% | 1,611,445 |
24-03-26 | 2.05 | -2.84% | 1,102,864 |
24-03-25 | 2.11 | +0.48% | 1,387,087 |
24-03-22 | 2.1 | -1.41% | 901,331 |
Delayed Quote Nasdaq, March 28, 2024 at 01:20 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.02% | 287M | |
+9.21% | 45.97B | |
+52.73% | 43.93B | |
+7.67% | 42.34B | |
-8.78% | 28.27B | |
+18.55% | 27.18B | |
-21.39% | 19.44B | |
+14.60% | 13.83B | |
+31.59% | 12.4B | |
+8.07% | 11.45B |